BioNova Pharmaceuticals Limited (BioNova) today announced that Center of Drug Evaluation (CDE) of National Medical Products Administration (NMPA) had approved its investigational new drug (IND) application for BN102 to conduct clinical trials in patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-cell Non-Hodgkin Lymphoma (NHL) in China.